TB Archives – Page 13 of 48 – Treatment Action Group

Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics

April 1, 2021
Dorrit Walsh

TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for diagnostics as a global norm; and increasing investments in alternative rapid molecular tests to promote competition and improve access.

Letters from TB Roundtable for Domestic and Global Appropriators, FY22

March 25, 2021
Dorrit Walsh

In March of 2021, the Tuberculosis Roundtable, of which TAG is a member organization, recently submitted letters to Congressional appropriators in support of increased funding for domestic and global TB programs for the 2022 fiscal year.

Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs

February 25, 2021
Dorrit Walsh

February 25, 2021 — TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and…

Community Movements Across Africa, Asia and South America Celebrate Roll-Out of Short-Course, Patient-Friendly TB Preventive Therapy

February 16, 2021
Dorrit Walsh

Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.

Open Letter: Urgent Action Necessary to Improve Equitable Access to GeneXpert TB Diagnostics and Achieve 1/4/6×24

February 2, 2021
Dorrit Walsh

A coalition of civil society activists, including TAG, public health leaders, and researchers sent this letter with information about the 1/4/6x24 Campaign...

Good COPs or Bad COPs: Promoting Interventions for Co-Infections and Advanced HIV Disease in 2021 PEPFAR Country Operational Plans (COPs)

January 21, 2021
Dorrit Walsh

On January 21, 2021, Treatment Action Group (TAG), Health GAP, and MSF Access Campaign presented this webinar on how to engage in PEPFAR COPs advocacy and promote the prioritization of interventions that address co-infections and advanced HIV disease.

2020 TAG Update

December 11, 2020
Dorrit Walsh

As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

Cover of Tuberculosis Research Funding Trends 2005-2019

2020 Report on TB Research Funding Trends

December 7, 2020
Dorrit Walsh

TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.

TAGline November 2020

November 11, 2020
Dorrit Walsh

'The Struggle of a Lifetime' (Continued): The words of the late Honorable John Lewis ring powerfully true today. In the U.S., as we welcome a new President-elect and Vice President-elect, we must also defend democracy to ensure a complete, peaceful transition of power. We engage in the struggles generations before us have advanced, despite myriad challenges and emerging new threats such as COVID-19.

Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement

November 9, 2020
Dorrit Walsh

Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.